Fortrea Holdings Inc.
Key Metrics
- Previous Close
- $18.14
- 52-Week Range
- $7.40 – $21.39
- Market Cap
- $1.73B
- P/E (TTM)
- —
- EPS (TTM)
- -0.83
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 3.30
- PEG Ratio
- 0.34
- Return on Equity
- -15.30%
- Return on Assets
- 0.58%
- Gross Margin
- 19.30%
- Operating Margin
- 2.58%
- Profit Margin
- -3.18%
- Current Ratio
- 0.96
- Debt/Equity
- 2.13
- Total Debt
- $1.12B
- Free Cash Flow
- $278.86M
- Revenue Growth
- -4.50%
- Earnings Growth
- —
- Enterprise Value
- $2.68B
Market Snapshot
About
Fortrea Holdings Inc. is a global contract research organization (CRO) providing clinical development and patient access services to biopharmaceutical and medical device companies. The company offers a comprehensive suite of services spanning Phase I through Phase IV clinical trials, including clinical trial management, data management, biostatistics, regulatory affairs, and medical writing. Fortrea was spun off from Labcorp in 2023 as a standalone publicly traded company. The company operates across multiple therapeutic areas and maintains a global presence with facilities and operations in numerous countries. Fortrea serves pharmaceutical and biotech companies of all sizes, from emerging biotechs to large multinational corporations.